NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
NEOGENOMICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$16.42−0.23 (-1.38%)
Close on Oct 19, 2026
- Market cap
- $2.15B
- P/E (TTM)
- –
- Dividend yield
- –
NEOGENOMICS INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $766.30M | $745.97M | $727.33M | $709.16M | $689.19M | $672.36M | $660.57M | – | – | – | – | – | 100.0% | +11.2% |
| Clinical Services | – | – | – | – | – | – | – | $551.76M | $533.53M | $515.30M | $495.64M | $473.74M | – | – |
| Advanced Diagnostics | – | – | – | – | – | – | – | $92.35M | $94.71M | $95.36M | $96.01M | $101.05M | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Client direct billing | $535.21M | $528.41M | $518.84M | $508.79M | $498.15M | $485.29M | $475.44M | – | – | – | – | – | 69.8% | +7.4% |
| Commercial insurance | $131.10M | $123.59M | $117.51M | $112.82M | $105.02M | $101.10M | $99.84M | – | – | – | – | – | 17.1% | +24.8% |
| Medicare and other government | $99.95M | $93.91M | $90.87M | $87.20M | $85.52M | $85.33M | $84.60M | – | – | – | – | – | 13.0% | +16.9% |
| Self-pay | – | – | – | $355.00K | $504.00K | $641.00K | $681.00K | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Neogenomics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.